|
Session 43
Oral Abstracts
HIV Vaccines and Immune Based Therapy
Wednesday, 4 - 6 pm
Room: Ballroom 1-2 |
Moderators: |
Michael Lederman
Case Western Reserve Univ, Cleveland, OH, US
Rafick-Pierre Sekaly
Univ of Montreal, Canada
|
| 4:00 pm 174 |
Efficacy of a Multigenic DNA/MVA Vaccine to Induce Mucosal Immune Responses and Protect against Repeated Low-dose Vaginal SIV Challenge
Marie-Claire Gauduin*1, A Carville1, P Kozlowski2, M Piatak3, B Felber3, G Pavlakis3, G Mazzara4, J Lifson3, C Miller5, and R Johnson1
1New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, US; 2Children's Hosp, Harvard Med Sch, Boston, MA, US; 3NCI, Frederick, MD, US; 4Therion Biologics, Cambridge, MA, US; and 5California Primate Res Ctr, Univ of California, Davis, US |
| 4:15 pm 175 |
Hepatitis B Surface Antigen Particles Possessing the HIV-1 gp41 Membrane Proximal Region
Sanjay Phogat*1, B Welcher1, J Muller2, M Connors3, J Mascola1, I Berkower2, and R Wyatt1
1Vaccine Res Ctr, NIAID, NIH, DHHS, Bethesda, MD, US; 2Ctr for Biologics Evaluation and Res, Food and Drug Admin, Bethesda, MD, US; and 3NIAID, NIH, DHHS, Bethesda, MD, US |
| 4:30 pm 176 |
Neutralization-sensitive HIV-1 Elicits Stronger Neutralizing Antibody Responses in Individuals with Recent HIV Infection
Simon Frost*1, S Little1, T Wrin2, Y Liu2, C Chappey2, C Petropoulos2, and D Richman1,3
1Univ of California, San Diego, US; 2Monogram Biosci, South San Francisco, CA, US; and 3VA San Diego Hlthcare System, CA, US |
| 4:45 pm 177 |
Fcg Receptor IIa and IIIa Polymorphisms Are Associated with the Risk of HIV Infection
Donald Forthal*1, G Landucci1, T Phan1, R Higa-Tanner1, and P Gilbert2
1Univ of California Sch of Med, Irvine, US and 2Statistical Ctr for HIV/AIDS Res and Prevention, Fred Hutchinson Cancer Res Ctr, Seattle, WA, US |
| 5:00 pm 178 |
Monoclonal Antibody Infusions Delay HIV-1 Rebound after Discontinuation of ART in a Cohort of HIV-1-infected Individuals Treated during Primary HIV-1 Infection
Saurabh Mehandru*1, B Vcelar2, M O'Neil1, T Wrin3, G Stiegler2, A Shet1, J Galovich3, C Petropoulos3, H Katinger2, and M Markowitz1
1Aaron Diamond AIDS Res Ctr, Rockefeller Univ, New York, NY, US; 2Polymun Sci, Vienna, Austria; and 3Monogram Biosci, South San Francisco, CA, US |
| 5:15 pm 179LB |
Hexon-chimeric Adenovirus Serotype 5 Vectors Effectively Circumvent Pre-existing Anti-vector Immunity
D Roberts1, A Nanda1, D Lynch1, B Ewald1, P Abbink1, M Havenga2, J Goudsmit2, and Dan Barouch*1
1Beth Israel Deaconess Med Ctr, Boston, MA, US and 2Crucell, Leiden, The Netherlands |
| 5:30 pm 180 |
Immune Responses that Successfully Control AIDS Virus Replication
David Watkins
Univ of Wisconsin Med Sch and Wisconsin Natl Primate Res Ctr, Madison, US |
|
